Upstream Bio, Inc. is trading 9.6% down at $7.30 on June 2, 2026, following a sharp intraday selloff despite a lack of new confirmed company-specific news or regulatory filings.
- The decline follows a period of heightened volatility linked to prior clinical trial data coverage and general biotech sector risk.
- Major U.S. indices are trading in slightly positive territory, suggesting the move is stock-specific rather than driven by broader market pressure.